Further trials sought for MRI (magnetic resonance imaging) contrast agent:
This article was originally published in Clinica
EPIX Medical and Mallinckrodt will seek US approval to begin Phase III trials of an injectable MRI contrast agent for detecting peripheral vascular disease following successful Phase II studies. The agent, called MS-325, was compared with the current X-ray angiography procedure and had an 82% accuracy in identifying clinically significant stenosis. EPIX, based in Cambridge, Massachusetts, said the agent could provide a minimally invasive way of visualising the peripheral vasculature early on in a patient's assessment and reduce the serious side-effects and complications associated with the highly invasive X-ray angiography procedure.
You may also be interested in...
Accord Healthcare is looking to breaking into the crowded market for biosimilar trastuzumab in the EU, after partner Henlius’ application was backed by the EMA’s CHMP. Meanwhile, a recommendation for a generic to the Eliquis anticoagulant was also forthcoming from the committee.
The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.
Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.